HBV'de Tedavi - EKMUD
HBV'de Tedavi - EKMUD
HBV'de Tedavi - EKMUD
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Asinetobakter Enfeksiyonları:<br />
<strong>Tedavi</strong><br />
dal sinerji gelişmektedir. A. baumannii’ye karşı<br />
bildirilen bu sinerji in vitro çalışmalarda gösterilmiştir.<br />
Beta-laktam ajanların kombinasyonu<br />
ile sinerji artışı gösterilmemiştir. Ancak, asinetobakter<br />
enfeksiyonlarının tedavisinde kombinasyon<br />
tedavisinin monoterapiden daha etkin<br />
olup olmadığı kesin değildir. Hastanın belirgin<br />
bir komorbiditesi yoksa monoterapi yeterli olabilir.<br />
Bakteriyofaj <strong>Tedavi</strong>si<br />
Son raporlar A. baumannii’nin faj tedavisine<br />
duyarlı olduğunu göstermektedir. Acinetobacter<br />
türlerine yönlendirilen bakteriyofaj, in vitro ve<br />
in vivo belirgin litik aktivite göstermektedir.<br />
Ancak ÇİD asinetobakter enfeksiyon tedavisine<br />
yönelik randomize, kontrollü çalışma bulunmadığı<br />
bilinmelidir.<br />
KAYNAKLAR<br />
1. Bassetti M, Righi E, Esposito S, et al. Drug treatment for<br />
multidrug-resistant Acinetobacter baumannii infections.<br />
Future Microbiol 2008;3:649-60.<br />
2. Bassetti M, Repetto E, Righi E, et al. Colistin and rifampicin<br />
in the treatment of multidrug-resistant Acinetobacter<br />
baumannii infections. J Antimicrob Chemother<br />
2008;61:417-20.<br />
3. Dauner DG, May JR, Steele JCH. Assessing antibiotic therapy<br />
for Acinetobacter baumannii infections in an academic<br />
medical center. Eur J Clin Microbiol Infect Dis<br />
2008;27:1021-4.<br />
266<br />
4. Falagas ME, Karveli EA, Siempos II. Acinetobacter infections:<br />
a growing threat for critically ill patients. Epidemiol<br />
Infect 2008;136:1009-19.<br />
5. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic<br />
review of the evidence from old and recent studies.<br />
Crit Care 2006;10:R27.<br />
6. Jones RN, Ferraro MJ, Reller LB, et al. Multicenter studies<br />
of tigecycline disk diffusion susceptibility results for<br />
Acinetobacter spp. J Clin Microbiol 2007;45:227-30.<br />
7. Kallel H, Bahloul M, Hergafi L, et al. Colistin as a salvage<br />
therapy for nosocomial infections caused by multidrugresistant<br />
bacteria in the ICU. Int J Antimicrob Agents<br />
2006;28:366-9.<br />
8. Michalopoulos A, Falagas ME. Treatment of Acinetobacter<br />
infections. Expert Opin Pharmacother 2010;11:779-88.<br />
9. Michalopoulos A, Tsiodras S, Rellos K, et al. Effectiveness<br />
and safety of colistin treatment in patients with ICUacquired<br />
infections due to multiresistant gram-negative<br />
bacteria: the renaissance of an old antibiotic. Clin<br />
Microbiol Infect 2005;11:115-21.<br />
10. Murray CK, Hospenthal DR. Treatment of multidrug resistant<br />
Acinetobacter. Curr Opin Infect Dis 2005;18:502-6.<br />
11. Mushtaq S, Ge Y, Livermore DM. Comparative activities<br />
of doripenem versus isolates, mutants, and transconjugants<br />
of Enterobacteriaceae and Acinetobacter spp. with<br />
characterized beta-lactamases. Antimicrob Agents<br />
Chemother 2004;48:1313-9.<br />
12. Zhanel GG, DeCorby M, Nichol KA, et al. Antimicrobial<br />
susceptibility of 3931 organisms isolated from intensive<br />
care units in Canada: Canadian National Intensive Care<br />
Unit Study, 2005/2006. Diagn Microbiol Infect Dis<br />
2008;62:67-79.<br />
3. Türkiye <strong>EKMUD</strong> Bilimsel Platformu
Change language